<DOC>
	<DOCNO>NCT00004158</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use holmium Ho 166 DOTMP may damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase I/II trial study effectiveness radiation therapy use holmium Ho 166 DOTMP plus melphalan peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose target radiotherapy use holmium Ho 166 DOTMP combine melphalan autologous syngeneic peripheral blood stem cell transplantation patient multiple myeloma . II . Determine response rate time progression patient treat regimen . OUTLINE : This dose escalation , multicenter study target radiotherapy use holmium Ho 166 DOTMP . Phase I : Autologous syngeneic peripheral blood stem cell ( PBSC ) harvest select CD34+ cell . Patients receive initial test dose holmium Ho 166 DOTMP IV . Patients adequate skeletal uptake test dose receive therapeutic dose holmium Ho 166 DOTMP IV 5-10 minute 1-3 day begin 2 day test dose infusion melphalan IV 20-30 minute day -3 . PBSC reinfused begin minimum 24 hour melphalan infusion ongoing radiation bone marrow fall less 1 rad/hour . Cohorts 4-7 patient receive escalate dos target radiotherapy use holmium Ho 166 DOTMP maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 7 patient experience dose limit toxicity . Phase II : Patients receive holmium Ho 166 DOTMP MTD phase I study . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 50 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Multiple myeloma one following : Complete partial response initial chemotherapy OR Primary refractory disease OR Chemotherapy responsive relapse Undergoing autologous syngeneic peripheral blood stem cell transplantation No myeloma refractory relapse PATIENT CHARACTERISTICS : Age : 18 physiologic 65 Performance status : Zubrod 02 Life expectancy : Not severely limited concurrent illness Hematopoietic : Not specify Hepatic : Bilirubin le 2 mg/dL SGPT le 4 time normal Renal : Creatinine clearance least 30 mL/min Cardiovascular : No uncontrolled arrhythmias symptomatic cardiac disease Pulmonary : No symptomatic pulmonary disease FEV1 , FVC , DLCO least 50 % predict Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No spinal cord compression PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Prior external beam radiotherapy exceed 30 Gy spinal cord great 20 % bone marrow volume Surgery : Not specify Other : At least 1 month since prior bisphosphonates No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>